BS_W9AT0MR7
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 19.080000000000002
- os_event
- true
- age_years
- 5.641
- sex
- M
- race
- African American
- new_clusters
- C5
- umap1_2d
- 6.107917314
- umap2_2d
- 5.431294401
- umap1_3d
- 2.781435154
- umap2_3d
- -0.00392169
- umap3_3d
- -2.021740851
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.340
- PANCREAS_BETA_CELLS+0.210
- SPERMATOGENESIS+0.180
- ESTROGEN_RESPONSE_EARLY+0.130
- HEDGEHOG_SIGNALING+0.090
- ESTROGEN_RESPONSE_LATE+0.060
- APICAL_SURFACE+0.040
- KRAS_SIGNALING_UP+0.020
- MYOGENESIS+0.010
- HEME_METABOLISM-0.030
Top 10 suppressed
- E2F_TARGETS-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.470
- MYC_TARGETS_V1-0.460
- MYC_TARGETS_V2-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- INTERFERON_ALPHA_RESPONSE-0.440
- DNA_REPAIR-0.430
- G2M_CHECKPOINT-0.410
- INTERFERON_GAMMA_RESPONSE-0.410
- OXIDATIVE_PHOSPHORYLATION-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_CQSAJ7BF | DNET | — | 0.947 |
| 2 | BS_0T17SY47 | low-grade glioma | — | 0.943 |
| 3 | MNG1280 | — | — | 0.942 |
| 4 | BS_K5802F84 | pilocytic astrocytoma | — | 0.936 |
| 5 | MNG700 | — | — | 0.935 |
| 6 | MNG906 | — | — | 0.935 |
| 7 | MNG1133 | — | — | 0.933 |
| 8 | MNG540 | — | — | 0.932 |
| 9 | BS_90B22NGP | ATRT | — | 0.932 |
| 10 | MNG226 | — | — | 0.931 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.020 | Inavolisib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |